SLC16A1 and neoplasm: MCT inhibitors such as AZD3965, AR-C155858, and α-cyano-4-hydroxycinnamate (CHC) reduce the levels of lactate in tumor cells via the inhibition of SLC16A1 and SLC16A7 (16, 17).